JP2012510457A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510457A5
JP2012510457A5 JP2011538050A JP2011538050A JP2012510457A5 JP 2012510457 A5 JP2012510457 A5 JP 2012510457A5 JP 2011538050 A JP2011538050 A JP 2011538050A JP 2011538050 A JP2011538050 A JP 2011538050A JP 2012510457 A5 JP2012510457 A5 JP 2012510457A5
Authority
JP
Japan
Prior art keywords
der
amb
bla
cla
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011538050A
Other languages
English (en)
Japanese (ja)
Other versions
JP5612592B2 (ja
JP2012510457A (ja
Filing date
Publication date
Priority claimed from GBGB0821806.7A external-priority patent/GB0821806D0/en
Application filed filed Critical
Publication of JP2012510457A publication Critical patent/JP2012510457A/ja
Publication of JP2012510457A5 publication Critical patent/JP2012510457A5/ja
Application granted granted Critical
Publication of JP5612592B2 publication Critical patent/JP5612592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011538050A 2008-11-28 2009-11-27 二量体形成の減少した組成物 Expired - Fee Related JP5612592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0821806.7A GB0821806D0 (en) 2008-11-28 2008-11-28 Compositions with reduced dimer formation
GB0821806.7 2008-11-28
PCT/GB2009/002767 WO2010061193A2 (en) 2008-11-28 2009-11-27 Compositions with reduced dimer formation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014180264A Division JP5905942B2 (ja) 2008-11-28 2014-09-04 二量体形成の減少した組成物

Publications (3)

Publication Number Publication Date
JP2012510457A JP2012510457A (ja) 2012-05-10
JP2012510457A5 true JP2012510457A5 (https=) 2013-01-24
JP5612592B2 JP5612592B2 (ja) 2014-10-22

Family

ID=40262373

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011538050A Expired - Fee Related JP5612592B2 (ja) 2008-11-28 2009-11-27 二量体形成の減少した組成物
JP2014180264A Expired - Fee Related JP5905942B2 (ja) 2008-11-28 2014-09-04 二量体形成の減少した組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014180264A Expired - Fee Related JP5905942B2 (ja) 2008-11-28 2014-09-04 二量体形成の減少した組成物

Country Status (20)

Country Link
US (3) US9180098B2 (https=)
EP (2) EP2373293B2 (https=)
JP (2) JP5612592B2 (https=)
KR (1) KR101669693B1 (https=)
CN (1) CN102227214B (https=)
AU (1) AU2009321358B2 (https=)
BR (1) BRPI0921541A2 (https=)
CA (1) CA2744587C (https=)
DK (1) DK2373293T3 (https=)
EA (1) EA019923B1 (https=)
ES (1) ES2427855T5 (https=)
GB (2) GB0821806D0 (https=)
HR (1) HRP20130933T1 (https=)
IL (1) IL213088A (https=)
MX (1) MX2011005530A (https=)
NZ (1) NZ593145A (https=)
PL (1) PL2373293T3 (https=)
SG (1) SG171438A1 (https=)
SI (1) SI2373293T1 (https=)
WO (1) WO2010061193A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
GB201301457D0 (en) * 2013-01-28 2013-03-13 Fluorogenics Ltd Freeze-dried composition
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
CN103656635B (zh) * 2013-12-05 2016-05-18 安徽润敏江生物科技有限公司 一种德国小蠊过敏原制剂的制备方法
PL3129001T3 (pl) * 2014-04-10 2020-06-29 Asit Biotech S.A. Preparat alergenów wolny od hsp
CA2973641A1 (en) * 2015-02-04 2016-08-11 Universitat Zurich Use of hla-b27 homodimers for cancer treatment
US20170136144A1 (en) 2015-11-12 2017-05-18 John C. Herr Compositions and methods for vas-occlusive contraception
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
AU2017230855B2 (en) 2016-03-08 2021-05-27 Universität Basel HLA-B57 open conformers
JP7010439B2 (ja) 2016-08-10 2022-01-26 ウニヴェルズィテート チューリッヒ ＭＨＣクラスＩａオープンコンフォーマー
EP4400166A3 (en) 2017-01-05 2025-01-22 Contraline, Inc. Methods for implanting and reversing stimuli-responsive implants
US12383421B2 (en) 2017-01-05 2025-08-12 Contraline, Inc. Contraceptive devices
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) * 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
JP7582939B2 (ja) 2018-11-13 2024-11-13 コントラライン，インコーポレイテッド 生体材料を送達するためのシステムおよび方法
CN116888267A (zh) * 2021-01-22 2023-10-13 先正达农作物保护股份公司 大豆工程化抗性

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (en) * 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4855407A (en) 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
JP2787162B2 (ja) * 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
ES2174822T3 (es) * 1989-11-03 2002-11-16 Immulogic Pharma Corp Una proteina felina reactiva con celulas t humanas (trfp) aislada de polvo domestico y usos para la misma.
DE69233772D1 (de) 1991-10-16 2009-11-12 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
CA2117779A1 (en) 1992-04-09 1993-10-28 Mei-Chang Kuo T cell epitopes of the major allergens from ambrosia artemisifolia
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
EP0783322A1 (en) 1994-09-02 1997-07-16 Immunologic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
GB2348808B (en) * 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
US7754686B2 (en) 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
AU2003215524A1 (en) * 2002-03-15 2003-09-29 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
WO2003093299A2 (en) 2002-05-06 2003-11-13 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
EP1685160A1 (en) 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
CN1913917B (zh) 2003-12-31 2012-02-01 正统逻辑公司 凝血酶肽衍生物的药物组合物
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
KR20070100832A (ko) 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
CN101171033A (zh) * 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
AU2006299310A1 (en) * 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation

Similar Documents

Publication Publication Date Title
JP2012510457A5 (https=)
Wood et al. Neonatal immunization: where do we stand?
Romano’ et al. Hepatitis B vaccination: a historical overview with a focus on the Italian achievements
Saso et al. Maternal immunization: nature meets nurture
JP2023526178A (ja) コロナウイルスワクチン
JP2012500194A5 (https=)
Verhasselt Is infant immunization by breastfeeding possible?
McKee et al. Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses
FI3250610T3 (fi) Fcrn-vasta-aineita ja menetelmiä niiden käyttämiseksi
JP2016519658A5 (https=)
Shoja et al. Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
Fernández et al. Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine
CN113301918A (zh) Cmv的通过融合修饰的病毒样颗粒
US10507234B2 (en) Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens
Guandalini et al. Celiac disease
Гладких Freund’s adjuvant is a classic of vaccine adjuvants and the basis of experimental immunology
Abdulla et al. The role of immunity in the pathogenesis of SARS-CoV-2 infection and in the protection generated by COVID-19 vaccines in different age groups
Aguilar et al. Action mechanisms and scientific rationale of using nasal vaccine (HeberNasvac) for the treatment of chronic hepatitis B
Yang et al. Display of streptococcus iniae α-enolase on the surface of virus-like particles (VLPs) of nervous necrosis virus (NNV) using SpyTag/SpyCatcher
Williman et al. The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun
Kang et al. Passive immunity and antibody response induced by toxoplasma gondii VLP immunization
Fan et al. Bioconjugated materials in the development of subunit vaccines
KR20220069992A (ko) 네이세리아 메닌기티디스 조성물 및 그의 방법
Suárez et al. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador
JP2015510878A5 (https=)